-

PharmaEssentia to Participate in Upcoming Jefferies and Citi Healthcare Conferences

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that members of its management team will participate in the following investor conferences:

Jefferies London Healthcare Conference
Date: November 16-19, 2026
Location: London, United Kingdom

Citi’s 2026 Global Healthcare Conference
Date: December 1-3, 2026
Location: Miami, Florida

Management will be available for investor meetings at both conferences. Investors interested in meeting with management should contact their Jefferies or Citi representative.

About PharmaEssentia
PharmaEssentia USA Corporation, located in Burlington, Massachusetts, is a subsidiary of PharmaEssentia Corporation (TWSE: 6446). PharmaEssentia Corporation, headquartered in Taipei, Taiwan, is a global and rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology, oncology, and immunology with one approved product and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan. For more information about PharmaEssentia USA, visit the website, LinkedIn or X (formerly Twitter).

Contacts

IR and Media Contacts
Muriel Huang
Director, Investor Relations and Corporate Communications
muriel_huang@pharmaessentia.com

Melia Matthews
Manager, Investor Relations and Corporate Communications
melia.matthews@pharmaessentia.com

PharmaEssentia USA Corporation

TSE:6446
Details
Headquarters: Taipei, Taiwan
CEO: Ko-Chung Lin
Employees: 600
Organization: PUB

Release Versions

Contacts

IR and Media Contacts
Muriel Huang
Director, Investor Relations and Corporate Communications
muriel_huang@pharmaessentia.com

Melia Matthews
Manager, Investor Relations and Corporate Communications
melia.matthews@pharmaessentia.com

Social Media Profiles
More News From PharmaEssentia USA Corporation

PharmaEssentia to Present Early-Stage Pipeline Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, Highlighting Immuno-Oncology Approaches for Solid Tumors

BEDFORD, Mass.--(BUSINESS WIRE)--PharmaEssentia Innovation Research Center (PIRC), a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced two poster presentations at the Society for Immunotherapy of Cancer's (SITC) 41st Annual Meeting, taking place November 4-8 in Phoenix, Arizona. The two presentations feature pre...

PharmaEssentia to Present Data at 18th International Congress on Myeloproliferative Neoplasms Highlighting Unmet Need with Current Therapies and Real-World Use of BESREMi® in Essential Thrombocythemia and Polycythemia Vera

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced six poster presentations at the 18th International Congress on Myeloproliferative Neoplasms, taking place October 29-30 in Brooklyn, New York. The presentations span essential thrombocythemia (...

PharmaEssentia to Present at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced two poster presentations at the 2026 Society of Hematologic Oncology (SOHO) Annual Meeting, which will be held September 9-12 in Houston, Texas. PharmaEssentia will present two-year results fro...
Back to Newsroom